Drugs / progenipoietin
last change Apr 2003 re-read 2 minutes ago

progenipoietin

also known as SD-9427
Developed for
cutaneous melanoma · ocular melanoma
Investigated by
National Cancer Institute (NCI) · University of Southern California

Trials 1 · a red edge is where a trial was stopped

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00005841 Jun → Dec 2000 cutaneous melanoma, ocular melanoma University of Southern California Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as progenipoietin ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005841
Known as SD-9427 “A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.” PMID 12684398 Apr 2003
Action Activate “SD-9427 (progenipoietin), an agonist of granulocyte colony-stimulating factor and the FLT-3 receptor” PMID 12684398 Apr 2003